Diabetic Polyneuropathy Clinical Trial
Official title:
Treatment of Painful Diabetic Neuropathy With Photon Stimulation
1. Objectives:
1. To assess the efficacy of Photon Stimulation compared with placebo, in treating the
pain of diabetic neuropathy.
2. To show that Photonic Stimulation for the treatment of painful diabetic neuropathy is
cost effective compared to traditional medical interventions. The latter will be
explored by an extensive search of the literature and from an equal number of patients
being treated in traditional medical practices using traditional medical interventions.
At the conclusion of the study the data will be analyzed for cost-benefits and the
possibility of crafting a best-practices approach to treat these syndromes that cost
billions of dollars a year in health care expenses and lost productivity.
2. Research Design
This is a double blinded, randomized, placebo-controlled study of 120 patients with painful
diabetic neuropathy. These 120 will be randomly assigned treatments utilizing Photon
Therapy, using a defined treatment protocol. We expect that some patients will drop out, and
our goal is 100 treated patients, for statistical purposes. The Photon Therapy group will be
split into two groups, one group that receives Active Photon Therapy and one group that will
be treated with the same type of equipment that has been modified to emit no infrared
photons (Non Active Photon Therapy Group ("Placebo")). The patients in the "Non Active
Photon Therapy Group" will be offered an Active Photon Treatment Session after completion of
the study. The patients in the Photon Therapy Groups will be randomized. There will also be
an Historical Control Group of patients, fifty, will have received traditional medical
interventions (e.g., narcotics, seizure medications) in traditional medical practices. Data
from these individuals will be used to calculate potential cost savings.
3. Methodology:
Subjects who meet the inclusion and exclusion criteria and have signed a valid informed
consent will be eligible to participate in the study. After screening, subjects in the
Photon Therapy groups (both active and nonactive) will undergo four treatment sessions. The
first treatment session will vary from the second, third and fourth. During all treatment
session, each patient will be imaged with the TIP Infrared Camera before, and after
treatment. Infrared imaging can visualize skin temperature changes in a noninvasive manner
(2). The first treatment will utilize slightly different protocol than subsequent visits,
reduced Photon dosage, 120 instead of 240 joules. Proprioception and protective sensation,
characterized by the Semmes-Weinstein monofilament test, and visual and analog pain scoring
will also be evaluated before and after each Photon Therapy treatment.
4. Finding:
To date, we have just completed 120 patients, using a block randomization scheme not
previously reported in this field. We have collected data on nerve function, pain, quality
of life, and skin circulation. The data will remain stored until the study is complete to
preserve the blinded nature of the project. Data analysis is still incomplete.
4. Clinical Significance
Diabetic neuropathy is a chronic and progressive condition that potentially leads to
disabling pain, and worse, amputation, for many individuals in the United States each year.
Present treatments utilize antiseizure medications, opiate analgesics, and antidepressants,
and are inconsistently effective. Development of a new treatment strategy potentially could
have significant benefit for a great many patients.
• PURPOSE, METHODS, AND PROCEDURES:
1. Purpose:
1. To assess the efficacy of Photon Stimulation compared with placebo, in treating the
pain of diabetic neuropathy.
2. To show that Photonic Stimulation for the treatment of painful diabetic neuropathy is
cost effective compared to traditional medical interventions. The latter will be
explored by an extensive search of the literature and from an equal number of patients
being treated in traditional medical practices using traditional medical interventions.
At the conclusion of the study the data will be analyzed for cost-benefits and the
possibility of crafting a best-practices approach to treat these syndromes that cost
billions of dollars a year in health care expenses and lost productivity.
2. Methods
This is a double blinded, randomized, placebo-controlled study of approximately 170 patients
with painful diabetic neuropathy. The study sample size is 170 patients. Of these 120 will
be given treatments utilizing Photon Therapy, using a defined treatment protocol. We plan to
recruit 120 patients to allow for drop out, and to provide 100 completed patients, as
requested by FDA. The Photon Therapy group will be split into two groups, one group that
receives Active Photon Therapy and one group that will be treated with the same type of
equipment that has been modified to emit no infrared photons (Non Active Photon Therapy
Group ("Placebo")). The patients in the "Non Active Photon Therapy Group" will be offered an
Active Photon Treatment Session after completion of the study. The patients in the Photon
Therapy Groups will be randomized. The Historical Control Group of patients, fifty, will
have received traditional medical interventions (e.g., narcotics, seizure medications) in
traditional medical practices.
3. Procedures: Subjects who meet the inclusion and exclusion criteria and have signed a
valid informed consent will be eligible to participate in the study. After screening,
subjects in the Photon Therapy groups (both active and nonactive) will undergo four
treatment sessions. The first treatment session will vary from the second, third and fourth.
During all treatment session, each patient will be imaged with the TIP Infrared Camera
before, and after treatment. Infrared imaging can visualize skin temperature changes in a
noninvasive manner (2). The first treatment will utilize slightly different protocol than
subsequent visits, reduced Photon dosage, 120 instead of 240 joules. Proprioception and
protective sensation, characterized by the Semmes-Weinstein monofilament test, and visual
and analog pain scoring will also be evaluated before and after each Photon Therapy
treatment.
- SUBJECT SELECTION: Subjects were initially recruited from the PI's clinic, from a list
of patients diagnosed by Dr. Beckley (Electromyographer) with painful diabetic
neuropathy, and from local referrals. In October 2004, we received permission to post
flyers and solicit patients (identified by Dr Beckley) from primary providers (flyer
and letter attached). We also recruited by posting flyers in VANCHCS facilities, and
with VANCHCS diabetes educators. Word of mouth also provided many subjects. In
September 2006 we modified the flyer to reflect a focused recruitment at Mather.
Vulnerable populations will not be studied.
- RISKS: The potential risks to subjects include physical, psychological, social and
economic. These are not likely: The physical risks include discomfort from the photon
machine. The psychological risks include boredom. The social risks include being
labeled as having a chronic illness, and the risk of loss of privacy. The economic risk
includes time off from work that may be needed to participate in the treatment program.
Confidentiality will be maintained as much as possible, by storing paper data in locked
offices, without name identifiers, and electronic data on spreadsheets on
password-protected computers in locked offices.
- BENEFITS: Individual subjects may derive benefit via pain relief; this would also
obtain to the whole group of patients with painful diabetic neuropathy.
- RISK-BENEFIT RATIO: The risk is minimal, and the benefit minimal to moderate
(potentially greater).
- SAFETY MONITORING: Research staff will monitor for safety.
- INFORMED CONSENT PROCEDURES: The PI (Dr. Swislocki) and his staff (Ms. Orth, Ms.
Weisshaupt) will conduct, obtain, and document informed consent within VANCHCS
facilities.
- PRIVACY AND CONFIDENTIALITY PROTECTIONS: Confidentiality will be maintained as much as
possible, by storing paper data in locked offices, without name identifiers, and
electronic data on spreadsheets on password-protected computers in locked offices.
- COSTS TO SUBJECTS: No added expenses are expected. No compensation is proposed.
- DISCLOSURE OF PERSONAL AND FINANCIAL INTEREST IN THE RESEARCH STUDY AND SPONSOR: The
Principal Investigator has no personal or financial interests in the research or
personal or financial interest in the entity.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06040567 -
Polyneuropathy, Impairments and Physical Activity - The PolyImPAct Study
|
||
Completed |
NCT02423434 -
Evaluation of Corneal Confocal Microscopy for the Identification and Prediction of Neuropathy in Type 1 Diabetes
|
||
Completed |
NCT05542901 -
Comparison of Joint Position Sense in Diabetic and Traumatic Transtibial Amputees
|
N/A | |
Withdrawn |
NCT01536236 -
Spinal Cord Stimulation for Diabetic Polyneuropathy
|
N/A | |
Active, not recruiting |
NCT01175928 -
Pneumatic Medicine: A Transformative Treatment for Diabetic Peripheral Neuropathy
|
Phase 1/Phase 2 | |
Completed |
NCT00993070 -
Efficacy and Safety Study of Topical Capsaicin in Painful Diabetic Neuropathy
|
Phase 2/Phase 3 | |
Completed |
NCT00278980 -
Effect of C-Peptide on Diabetic Peripheral Neuropathy
|
Phase 2 | |
Completed |
NCT04593992 -
HTEMS Treatment of Diabetic Polyneuropathy
|
N/A | |
Completed |
NCT01465620 -
Dietetic and Hygiene Measures in Metabolic Neuropathies: the Neurodiet Study
|
Phase 3 | |
Completed |
NCT01079325 -
Clinical Trial of SB-509 in Subjects With Diabetic Neuropathy
|
Phase 2 | |
Completed |
NCT00406458 -
Clinical Trial of SB-509 in Subjects With Diabetic Neuropathy
|
Phase 2 | |
Recruiting |
NCT06072573 -
Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Diabetic Polyneuropathy
|
Phase 3 | |
Recruiting |
NCT06071975 -
Long Term Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Diabetic Polyneuropathy
|
Phase 3 | |
Recruiting |
NCT05521737 -
Effect of Electroacupuncture on Sensitive Symptoms of Distal Diabetic Peripheral Neuropathy
|
N/A | |
Completed |
NCT01847937 -
Magnetic Resonance Diagnostics of Diabetic Peripheral Neuropathy
|
N/A | |
Completed |
NCT00476931 -
Clinical Trial of SB-509 in Subjects With Diabetic Neuropathy
|
Phase 2 | |
Completed |
NCT00977483 -
Assessment of Efficacy and Safety of Thioctic Acid in the Oral Treatment of Diabetic Polyneuropathy (Stage 1 or 2)
|
Phase 3 | |
Completed |
NCT01006915 -
Surgical Decompression for Diabetic Neuropathy in the Foot
|
N/A | |
Completed |
NCT00501202 -
Study for Safety and Effectiveness of RWJ-333369 (Carsibamate) for the Treatment of Diabetic Peripheral Neuropathy (DPN).
|
Phase 2 | |
Completed |
NCT00307749 -
Safety and Efficacy of MCC-257 in the Treatment of Diabetic Polyneuropathy
|
Phase 2 |